// App-Quantinova.ai

1384 : Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Researchers

Presenter

  • Michael W. Schuster

Principal Investigators

  • Jason Westin

  • Jose M Zijlstra

  • George A Follows

  • Reem Karmali

  • Nagesh Kalakonda

  • Andre H. Goy

  • Rene-Olivier Casasnovas

  • Joost Vermaat

  • Eric Van Den Neste

  • Sylvain Choquet

  • Catherine Thieblemont

  • Federica Cavallo

  • Maria de Fatima De La Cruz

  • Brian T. Hill

  • Herve Tilly

  • Shireen Kassam

  • Reda Bouabdallah

  • Ulrich Jaeger

  • Ronit Gurion

  • Paolo Caimi

  • Peter Martin

  • Andrew Davies

  • Sonali M. Smith

  • Graham P. Collins

  • Fritz Offner

  • Gilles Salles

  • Xiwen Ma

  • Kelly Corona

  • Jean-Richard Saint-Martin

  • Anita A. Joshi

  • Kamal Chamoun

  • Hongwei Wang

  • Jatin J. Shah

  • Sharon Shacham

  • Michael G Kauffman

  • Marie Maerevoet

Medical Centers

  • Stony Brook University, Stony Brook, NY

  • Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hematology, Amsterdam UMC, Vrije Universiteit Cancer Center, Amsterdam, Netherlands

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • Division of Hematology, Northwestern Medical Faculty Foundation, Chicago, IL

  • University of Liverpool, Liverpool, United Kingdom

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Hématologie Clinique and INSERM 1231, CHU Dijon,Dijon,France

  • Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Gruope Hospitalier Pitie-Salpetriere, Paris, France

  • Department of Immuno hematology, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France

  • Diderot University, University de Paris, Paris, France

  • Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • CRLCC Henri Becquerel, Rouen, France

  • Kings College London, London, United Kingdom

  • Institut Paoli-Calmettes, Marseille, France

  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

  • Rabin Medical Center, Petach Tikvah, Israel

  • University Hospitals Case Medical Center, Cleveland, OH

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Department of Radiology, University of Chicago, Chicago, IL

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • University Hospital Gent, Gent, Belgium

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • Karyopharm Therapeutics, Newton, MA

  • Karyopharm Therapeutics, Newton, MA

  • Institute Jules Bordet, Brussels, Belgium

Locations

  • United States

  • Spain

  • Netherlands

  • United Kingdom

  • France

  • Italy

  • Austria

  • Israel

  • Belgium

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Creatinine

Drug/Treatment

  • Selinexor

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved